Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Yea...(1 1231 Adjusted EBITDA ...)

Adjusted EBITDA of Warner Chilcott Holdings

Company III, Limited., as defined $120,842 $ 95,264

Note: Warner Chilcott Holdings Company III, Limited and certain of its

subsidiaries are parties to our credit agreement and the indenture

governing our Senior Subordinated Notes due 2015. Certain expenses

included in Warner Chilcott Limited's ("WCL") consolidated operating

results are not deducted in arriving at Adjusted EBITDA for Warner

Chilcott Holdings Company III, Limited and its subsidiaries.

WARNER CHILCOTT LIMITED

REVENUE BY PRODUCT

(In millions of U.S. dollars)

(Unaudited)

Quarter Ended

Mar-31-08 Mar-31-07

Oral Contraception ("OC")

LOESTRIN 24-FE $ 46.9 $ 34.4

FEMCON FE 10.8 5.0

ESTROSTEP FE / TILIA 4.7 22.0

OVCON / ZENCHENT 2.7 4.6

Total OC 65.1 66.0

Hormone therapy ("HT")

ESTRACE Cream 19.2 15.7

FEMHRT 16.0 13.2

FEMRING 3.5 3.5

Other HT products 2.9 4.0

Total HT 41.6 36.4

Dermatology

DORYX 35.1 26.7

TACLONEX 36.9 29.2

DOVONEX 33.2 41.9

Total Dermatology 105.2 97.8

PMDD

SARAFEM
'/>"/>